The 36-month beta value for ALT is also noteworthy at 0.89. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALT is 76.22M, and at present, short sellers hold a 28.42% of that float. The average trading volume of ALT on March 17, 2025 was 2.45M shares.
ALT) stock’s latest price update
The stock of Altimmune Inc (NASDAQ: ALT) has increased by 13.85 when compared to last closing price of 5.20.Despite this, the company has seen a gain of 6.28% in its stock price over the last five trading days. reuters.com reported 2025-03-13 that Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.
ALT’s Market Performance
Altimmune Inc (ALT) has experienced a 6.28% rise in stock performance for the past week, with a -4.82% drop in the past month, and a -34.30% drop in the past quarter. The volatility ratio for the week is 7.76%, and the volatility levels for the past 30 days are at 7.35% for ALT. The simple moving average for the past 20 days is -1.28% for ALT’s stock, with a -15.05% simple moving average for the past 200 days.
Analysts’ Opinion of ALT
Stifel, on the other hand, stated in their research note that they expect to see ALT reach a price target of $18. The rating they have provided for ALT stocks is “Buy” according to the report published on January 08th, 2025.
UBS gave a rating of “Buy” to ALT, setting the target price at $26 in the report published on November 12th of the previous year.
ALT Trading at -8.89% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.95% of loss for the given period.
Volatility was left at 7.35%, however, over the last 30 days, the volatility rate increased by 7.76%, as shares sank -4.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.13% lower at present.
During the last 5 trading sessions, ALT rose by +6.28%, which changed the moving average for the period of 200-days by -19.24% in comparison to the 20-day moving average, which settled at $6.00. In addition, Altimmune Inc saw -17.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from WEAVER GREGORY L, who purchase 10,000 shares at the price of $5.20 back on Mar 13 ’25. After this action, WEAVER GREGORY L now owns 10,000 shares of Altimmune Inc, valued at $51,996 using the latest closing price.
Drutz David, the Director of Altimmune Inc, sale 16,011 shares at $6.90 during a trade that took place back on Aug 19 ’24, which means that Drutz David is holding 41,958 shares at $110,547 based on the most recent closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -5158.6 for the present operating margin
- -7.4 for the gross margin
The net margin for Altimmune Inc stands at -4752.95. The total capital return value is set at -0.8. Equity return is now at value -59.86, with -54.33 for asset returns.
Based on Altimmune Inc (ALT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -47.5. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11463.56.
Currently, EBITDA for the company is -94.81 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 21033.81. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.10.
Conclusion
In summary, Altimmune Inc (ALT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
